Rasopathies - Dysmorphic syndromes with short stature and risk of malignancy

Endocrine Regulations

Volumn 47, Issue 4, 2013, Pages 217-222

  Cizmarova, M ^a   Kostalova, L ^a   Pribilincova, Z ^a   Lasabova, Z ^b   Hlavata, A ^a   Kovacs, L ^a   Ilencikova, D ^a  

^a Bratislava   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

Leukemia; RAS MAPK signaling pathway; Rasopathies; Tumor

Indexed keywords

B RAF KINASE; CBL PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; K RAS PROTEIN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; RAS PROTEIN; SORAFENIB; SOS PROTEIN;

ARTICLE; BODY DYSMORPHIC DISORDER; CANCER RISK; CARDIO FACIO CUTANEOUS SYNDROME; CLINICAL EXAMINATION; COSTELLO SYNDROME; DEVELOPMENTAL DISORDER; GENETIC ASSOCIATION; HUMAN; HYPERKERATOSIS; LEOPARD SYNDROME; MOLECULAR DIAGNOSTICS; NEOPLASM; NEUROFIBROMA; NONHUMAN; NOONAN SYNDROME; PROFESSIONAL KNOWLEDGE; RASOPATHY; SIGNAL TRANSDUCTION;

BODY HEIGHT; COSTELLO SYNDROME; ECTODERMAL DYSPLASIA; FACIES; FAILURE TO THRIVE; HEART DEFECTS, CONGENITAL; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; NEUROFIBROMATOSES; NOONAN SYNDROME; RAS PROTEINS; RISK FACTORS;

EID: 84886648436     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: 10.4149/endo_2013_04_217     Document Type: Article

References (31)

1. Allanson JE, Hall JG, Van Allen MI: Noonan phenotype associated with neurofbromatosis. American Journal of Medical Genetics 21, 457-462, 1985.http://dx.doi.org/10.1002/ajmg.1320210307
2. Amoroso A, Garzia P, Vadacca M, Galluzzo S, Del Porto F, Mitterhofer A P, Afeltra A: Te unusual association of three autoimmune diseases in a patient with Noonan syndrome. J Adol Health 32, 94-97, 2003.http://dx.doi.org/10.1016/ S1054-139X(02)00364-6
3. Bentires-Alj M, Kontaridis MI, Neel BG: Stops along the RAS pathway in human genetic disease. Nat Med 12, 283-285, 2006.http://dx.doi.org/10.1038/nm0306-283
4. Cirstea IC, Kutsche K, Dvorsky R, Gremer L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, Konig R, Kratz C P, Pantaleoni F, Dentici ML, Joshi VA, Kucherlapati RS, Mazzanti L, Mundlos S, Patton MA, Silengo MC, Rossi C, Zampino G, Digilio C, Stuppia L, Seemanova E, Pennacchio LA, Gelb BD, Dallapiccola B, Wittinghofer A, Ahmadian MR, Tartaglia M, Zenker M: A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet 42, 27-29, 2010.http://dx.doi.org/10.1038/ng.497
5. Costello JM: A new syndrome. NZ Med J 74: 397, 1971.
6. Digilio MC, Sarkozy A, de Zorzi A, Pacileo G, Limongelli G, Mingarelli R, Calabro R, Marino B, Dallapiccola B: LEOPARD syndrome: clinical diagnosis in the first year of life. American Journal of Medical Genetics 140A, 740-746, 2006.http://dx.doi.org/10.1002/ajmg.a.31156
7. Gripp KW: Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137C, 72-77, 2005.http://dx.doi.org/10.1002/ajmg.c.30065
8. Koudova M, Seemanova E, Zenker M: Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence. Eur J Med Genet 52, 337-340, 2009.http://dx.doi.org/10.1016/j.ejmg.2009.04.006
9. Krammer U, Wimmer K, Wiesbauer P, Rasse M, Lang S, Mullner-Eidenbock A, Frisch H: Neurofbromatosis 1: a novel NF1 mutation in an 11-year-old girl with a giant cell granuloma. J Child Neurol 18, 371-373, 2003.http://dx.doi.org/10.1177/08830738030180051901
10. Kratz CP: Myeloproliferative disease and cancer in persons with Noonan syndrome and related disorders. In: Zenker M, editor. Monographs in human genetics 17, 119-127, 2009.
11. Kratz C P, Rapisuwon S, Reed H, Hasle H, Rosenberg PS: Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 157, 83-89, 2011.http://dx.doi.org/10.1002/ajmg.c.30300
12. Lepri F, De Luca A, Stella L, Rossi C, Baldassarre G, Pantaleoni F, Cordeddu V, Williams BJ, Dentici ML, Caputo V, Venanzi S, Bonaguro M, Kavamura I, Faienza MF, Pilotta A, Stanzial F, Faravelli F, Gabrielli O, Marino B, Neri G, Silengo MC, Ferrero GB, Torrrente I, Selicorni A, Mazzanti L, Digilio MC, Zampino G, Dallapiccola B, Gelb BD, Tartaglia M: SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotypephenotype correlations. Hum Mutat 32, 1-13, 2001.
13. Li W, Cui y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ: The HMGCoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofbromatosis type 1. Curr Biol 15, 1961-1967, 2005. http://dx.doi.org/10.1016/j.cub.2005.09.043
14. Lisbona M P, Moreno M, Orellana C, Gratacos J, Larrosa M: Noonan syndrome associated with systemic lupus erythema-tosus. Lupus 18, 267-269, 2009.http://dx.doi.org/10.1177/0961203308094996
15. Lopez-Rangel E, Malleson PN, Lirenman DS, Roa B, Wiszniewska J, Lewis ME: Systemic lupus erythematosus and other autoimmune disorders in children with Noonan syndrome. Am J Med Genet A 139, 239-242, 2006.
16. Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, Caputo V, Silvano M, Buscherini F, Consoli F, Ferrara G, Digilio MC, Cavaliere ML, van Hagen JM, Zampino G, van der Burgt I, Ferrero GB, Mazzanti L, Screpanti I, yntema HG, Nillesen WM, Savarirayan R, Zenker M, Dallapiccola B, Gelb BD, Tartaglia M: Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 87, 250-257, 2010.http://dx.doi.org/10.1016/j.ajhg.2010.06.015
17. Mustelin T. Are other protein tyrosine phosphatases than PTPN22 associated with autoimmunity? Semin Immunol 18, 254-260, 2006.http://dx.doi.org/10.1016/j.smim.2006.03.013
18. Noonan JA: Hypertelorism with Turner phenotype. Am J Dis Child 116, 373-380, 1968.
19. Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA: The Ullrich-Noonan syndrome (Turner phenotype). American Journal of Diseases of Children 127, 48-55, 1974.
20. Origone P, Deferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP: Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet 118, 309-313, 2003.http://dx.doi.org/10.1002/ajmg.a.10167
21. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, López Siguero J P, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD: Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39, 1007-1012, 2007.http://dx.doi.org/10.1038/ng2073
22. Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, Miles P V, Opitz JM: New multiple congenital anomalies/ mental retardation syndrome with cardio-facio-cutaneous involvement - the CFC syndrome. Am J Med Genet 25, 413-427, 1986.http://dx.doi.org/10.1002/ajmg.1320250303
23. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, young T, Neri G: The cardiofaciocutaneous syndrome. J Med Genet 43, 833-842, 2006.http://dx.doi.org/10.1136/jmg.2006.042796
24. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA: Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 126, 746-759, 2010.http://dx.doi.org/10.1542/peds.2009-3207
25. Sarkozy A, Digilio MC, Zampino G, Dallapiccola B, Tartaglia M, Gelb BD, Zenker M: LEOPARD syndrome: clinical aspects and molecular pathogenesis. In Zenker M (ed.). Noonan Syndrome and Related Disorders. Monographs in Human Genetics 17, 55-65, 2009.
26. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang Ky, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP: Germline KRAS mutations cause Noonan syndrome. Nat Genet 38, 331-336, 2006. http://dx.doi.org/10.1038/ng1748
27. Stiller CA, Chessells JM, Fitchett M: Neurofbromatosis and childhood leukaemia/ lymphoma: a populationbased UK-CCSG study. Br J Cancer 70, 969-972, 1994. http://dx.doi.org/10.1038/bjc.1994.431
28. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucher-lapati RS, Jefery S, Patton MA, Gelb BD: PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70, 1555-1563, 2002.http://dx.doi.org/10.1086/340847
29. Tartaglia M, Gelb BD, Zenker M: Noonan syndrome and clinically related disorders. Best Pract Res ClinEndocrinolMetab 25, 161-179, 2011.http://dx.doi.org/10.1016/j.beem.2010.09.002
30. Tidyman WE, Rauen KA: The Rasopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Current Opinion in Genetics and Development 19, 230-236, 2009.http://dx.doi.org/10.1016/j.gde.2009.04.001
31. Vang T, Miletic AV, Bottini N, Mustelin T: Protein tyrosine phosphatase in human autoimmunity. Autoimmunity 40, 453-461, 2007.http://dx.doi.org/10.1080/08916930701464897